Kyntra Bio, Inc. (NASDAQ:KYNB) Q4 2025 Earnings Call Transcript March 16, 2026 Kyntra Bio, Inc. beats earnings expectations.

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, ...

Prostate-specific membrane androgen PET/CT can help clinicians intensify or de-escalate care for men with prostate cancer who ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.

The 2026 European Association of Urology (EAU) annual meeting featured a PARP inhibitors for prostate cancer session and a presentation by Dr. Martin Gleave discussing how to optimize tissue biopsy ...

Monte Rosa (GLUE) shares rise as it teams with Johnson & Johnson to test MRT-2359 + ERLEADA in mCRPC AR mutations in a Phase ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in ...

Early-stage prostate cancer rarely causes symptoms, making routine screening the most reliable way to catch it before it ...

Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...

The 2026 European Association of Urology (EAU) annual meeting featured an advancement in metastatic castration resistant ...

Prostate cancer is one of the most common cancers affecting men around the world. It develops in the prostate, a small gland ...